Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

Maastricht University Medical Center, Maastricht, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:3City/State/Province:Maastricht
Treatments:Biologic therapyHospital:Maastricht University Medical Center
Drugs:Journal:Link
Date:Feb 2013

Description:

Patients:
This phase 2 study involved 57 advanced non-small cell lung cancer patients who had previously been treated with platinum-based chemotherapy. Their cancer was classified as having the KRAS mutation. The median patient age was 58.5 years and 28.1% were male.

Treatment:
Patients were treated with the biologic therapy agent called sorafenib.

Toxicities:
The most severe toxicities were of grade 3 and included hand-foot skin reaction, rash, and diarrhea.

Results:
The median overall survival was 5.3 months.

Support:
This study was funded by Bayer Pharmaceuticals.

Correspondence: Dr. Egbert F. Smit; email: [email protected]



Back